Abstract:The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and/or intestinal diseases.

The gut–liver axis in sepsis: interaction mechanisms and therapeutic potential

Gut-liver crosstalk in sepsis-induced liver injury

The liver-gut-axis: initiator and responder to sepsis

The role of 'brain gut axis' in the development of sepsis

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases

Research progress on the role of gut microbiota and its metabolites in the occurrence and development of septic-associated liver injury

[Role and mechanism of intestinal-liver interaction in infectious intestinal/liver injury]

Infectious Microecology in Liver Disease

Gut Leakage of Fungal-Derived Inflammatory Mediators: Part of a Gut-Liver-Kidney Axis in Bacterial Sepsis

Inflammatory liver diseases and susceptibility to sepsis

Gut-Lung Crosstalk in Sepsis-Induced Acute Lung Injury

The Gut Microbiota Contributes to Systemic Responses and Liver Injury in Gut-Derived Sepsis

Liver — guardian, modifier and target of sepsis

The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases

The gut-liver axis in immune remodeling of hepatic cirrhosis

Neuroendocrine immune network and sepsis

Gut‐liver axis in liver disease: From basic science to clinical treatment (Review)

The gut–liver axis and gut microbiota in health and liver disease

Advances in sepsis-associated liver dysfunction

Crosstalk Between Liver Macrophages and Gut Microbiota: an Important Component of Inflammation-Associated Liver Diseases

Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg